Japan, Sept. 16 -- UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES:THE,LENTIGEN TECHNOLOGY INC has got intellectual property rights for 'COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-ROR1 IMMUNOTHERAPY.' Other related details are as follows:
Application Number: JP,2025-094057
Category (FI): A61K35/76,C07K16/28,C07K14/435,C12N15/85@Z,A61K35/17,C12N15/13,A61K31/7088,C12N5/0783,C12N5/10,C12N1/21,C12N1/19,C12N1/15,C12N1/13,C12N15/12,C12N15/62@Z,A61K40/31,A61P35/00,A61P35/02,C12N15/861@Z,C12N15/867@Z,C12N15/869@Z,C07K19/00,A61K48/00,A61K39/395@N,A61K35/761,C12N15/63@Z,C12N15/11@Z
Stage: PROBLEM TO BE SOLVED: To provide chimeric antigen receptors comprising ROR1 antigen binding domain, and nucleic acid, recombinant expression vector, host cell, antigen binding fragment, and pharmaceutical composition related to the chimeric antigen receptors, as well as methods for treating or preventing cancer in subjects and methods for preparing chimeric antigen receptor T cells.SOLUTION: Provided herein is an isolated nucleic acid molecule encoding a chimeric antigen receptor comprising: at least one extracellular antigen binding domain comprising an ROR1 antigen binding domain encoded by a specific nucleotide sequence; at least one transmembrane domain; and at least one intracellular signaling domain.SELECTED DRAWING: Figure 1 (Grant)
Filing Date: June 5, 2025
Publication Date: Sept. 9, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
